09:00 - 09:15 Opening & Welcome

09:15 - 10:00 Keynote: Classification and epidemiology of secondary and therapy-related leukemias

Chair: Maria Teresa Voso (Italy)

• Coleman Lindsley (United States)

10:00 - 10:30 Coffee break

10:30 - 11:45 Session 1: Susceptibility and mechanisms of secondary leukemogenesis

Chair: Shahram Kordasti (United Kingdom)

• BM-failure syndromes
  Carmelo Gurnari (Italy)
• DDX41 and other susceptibility genes
  Marie Sebert (France)
• TP53 and other classifier mutations
  Andrew Wei (Australia)
• Panel discussion
  All speakers

11:45 - 13:00 Oral Abstracts Session 1

Chairs: Kirsten Grønbæk (Denmark) & Konstanze Döhner (Germany)

• NAVIGATING THE BORDERLAND OF SECONDARY ΑΜL: REFINING THE DIAGNOSTIC QUALIFIERS AND EVALUATING THE IMPACT OF 20% BLAST THRESHOLD
  Enrico Attardi (Italy)
• HIGHLY VARIABLE ALTERNATIVE SPLICING PROFILES IN SPLICEOSOME-MUTATED SECONDARY AML REVEALED BY LONG-READ SINGLE-CELL SEQUENCING
  Jonas Berger (Germany)
• COMPREHENSIVE MULTI-OMICS EXPLORATION OF MOUSE MODELS REFLECTING RECURRENT MUTATIONS OF HUMAN AML
  Paul Jung (Germany)
• CANCER GENE DISCOVERY IN ASXL1-MUTATED AML THROUGH SINGLE-CELL TRANSPOSON AND TRANSCRIPTOME SEQUENCING
  Francis Baumgartner (Germany)
• CARTOGRAPHY OF CLINICAL AND MOLECULAR FEATURES OF THERAPY-RELATED MYELOID NEOPLASMS: INSIGHTS FROM THE ITALIAN REGISTRY
  Elisa Meddi (Italy)
• SWING BETWEEN TWO LINEAGES. THE EXCEPTIONAL CASE OF PRIMARY MYELOFIBROSIS TRANSFORMATION TO ACUTE LYMPHOBLASTIC LEUKEMIA AND SUBSEQUENT RELAPSE OF ACUTE MYELOID LEUKEMIA
  Magdalena Karasek (Poland)

13:00 - 14:00 Lunch break

Breakout Sessions

14:00 - 15:30 Breakout A: Drugs and diseases in th-related AML

Chair: Jordi Sierra (Spain)

• Solid tumors and PARPi
  Elisabetta Todisco (Italy)
• Hematologic malignancies (topo-II inhibitors, lenalidomide, autologous transplantation)
  Sylvain Garciaz (France)
• Secondary leukemias with recurrent genetic abnormalities
  Coleman Lindsley (United States)

14:00 - 15:30 Breakout B: Exploring the multifactorial events of AML transformation

Chair: Paresh Vyas (United Kingdom)

• Quantitative dynamics for transformation of MDS to AML
  Verena Korber (United Kingdom)
• AML microenvironment
  Dominique Bonnet (United Kingdom)
• Modelling secondary AML using human iduced pluripotent stem cells
  Eirini Papapetrou (United States)

15:30 - 15:45 Coffee break

15:45 - 17:00 Session 2: Mechanisms of clonal progression

Chair: Christoph Plass (Germany)

• CHIP and clinical management
  Kirsten Grønbæk (Denmark)
• Clonal trajectories from normal hemopoiesis to clonal hemopoiesis (CH and CCUS) to MDS and MPD and then to AML
  Coleman Lindsley (United States)
• Progressive immune remodeling as hemopoiesis changes over time from normal hemopoiesis to sAML
  Shahram Kordasti (United Kingdom)
• Panel discussion
  All speakers

17:00 - 18:00 AbbVie Satellite Symposium: Therapeutic Strategies and Novel Insights in Secondary AML: Sharing Expert Knowledge

• Welcome and Introduction 
  Konstanze Döhner (Germany)
• Therapeutic Strategies and Novel Insights in Secondary AML: Sharing Expert Knowledge
  Franziska Modemann (Germany)
• Targeting Complexity: The Role of Genetic Profiles in secondary AML
  Lars Bullinger (Germany)
• Panel Discussion
  
• Closing Remarks
  Konstanze Döhner (Germany)
  

18:00 - 19:00 Welcome reception & poster walk

08:30 - 09:15 Keynote: Complex karyotype in sAML

Chair: Konstanze Döhner (Germany)

• Christoph Plass (Germany)

09:15 - 10:30 Session 3: Special situations

Chair: Carmelo Gurnari (Italy)

• sAML in childhood (including after gene-therapy)
  Pietro Merli (Italy)
• After CAR-T cell treatment
  Michael Hudecek (Germany)
• Donor-derived leukemias after HSCT
  Daniel Wiseman (United Kingdom)
• Panel discussion 

10:30 - 10:45 Coffee break

10:45 - 12:00 Oral Abstract Session 2

Chair: Maria Teresa Voso (Italy) & Marie Sebert (France)

• PHYLOGENETICS OF MDS-TO-AML PROGRESSION AT SINGLE-CELL RESOLUTION: A GENETIC AND EPIGENETIC APPROACH TO UNRAVEL CLONES RESISTANT TO HYPOMETHYLATING AGENTS
  Ignacio Campillo-Marcos (Spain)
• HIGH RISK MUTATIONS IN CRITICAL GENES DO NOT SIGNIFICANTLY AFFECT REMISSION RATES AND MRD CLEARANCE IN AML PATIENTS RECEIVING CPX-351 INDUCTION
  Paola Minetto (Italy)
• EFFICACY OF CPX-351 IN SECONDARY ACUTE MYELOID LEUKEMIA DEFINED ACCORDING TO WHO 2022 CLASSIFICATION
  Fabio Guolo (Italy)
• COMPARING OUTCOMES BETWEEN CPX-351 AND FLUDARABINE-BASED INDUCTION IN SECONDARY ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING: THE PROGNOSTIC ROLE OF MEASURABLE RESIDUAL DISEASE
  Carola Riva (Italy)
• ANALYSIS OF GERMLINE VARIANTS IN TAIWANESE PEDIATRIC AML PATIENTS: FOCUS ON SECONDARY AML AND FAMILY CANCER HISTORY
  Der-Shiun Wang (Taiwan)
• RETROSPECTIVE EVALUATION OF THERAPY-RELATED ACUTE MYELOID LEUKEMIAS: A SINGLE CENTER EXPERIENCE
  Denis Cetin (Türkiye)

12:00 - 13:00 Session 4: Treatment

Chair: Andrew Wei (Australia)

• Conventional CHT
  Christian Recher (France)
• Semi-intensive treatment
  Andrew Wei (Australia)
• Transplant-related issues in sAML
  Jorge Sierra (Spain)
• Panel discussion
  All speakers

13:00 - 13:15 Takeaways & Closing

13:15 - 14:00 Farewell lunch